Article Text

Download PDFPDF

Mode of action of maintenance immunotherapy therapy with the TLR-9 agonist MGN1703 in metastatic colorectal carcinoma: the Phase III IMPALA study
  1. Alexander Stein1,
  2. Kerstin Kapp2,
  3. Werner Scheithauer3,
  4. Ramon Salazar4,
  5. Michel Ducreux5,
  6. Tom Waddell6,
  7. Dirk Arnold7,
  8. Christophe Tournigand8,
  9. Alberto Sobrero9,
  10. Eric Van Cutsem10,
  11. Manuel Schmidt2 and
  12. David Cunningham6
  1. Aff1 grid.412315.0University Cancer Center Hamburg Hamburg Germany
  2. Aff2 grid.476508.80000000449115108Mologen AG Berlin Germany
  3. Aff3 grid.22937.3d0000000092598492Medical University of Vienna Vienna Austria
  4. Aff4 grid.418701.b0000000120978389Institut Català D´Oncologia Barcelona Spain
  5. Aff5 grid.14925.3b0000000122849388Gustave Roussy Cancer Campus Grand Paris Villejuif France
  6. Aff6 grid.424926.f0000000404170461Royal Marsden Hospital London UK
  7. Aff7 grid.7708.80000000094287911Klinik für Tumorbiologie Freiburg Germany
  8. Aff8 grid.412116.10000000122921474Hôpital Henri Mondor Créteil France
  9. Aff9 IRCCS Ospedale San Martino IST Genova Italy
  10. Aff10 grid.410569.f0000000406263338University Hospitals Gasthuisberg Leuven Belgium

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts


MGN1703, a potent immunomodulatory Toll-like receptor 9 (TLR-9) agonist, was compared to placebo in the previous double-blind, randomized Phase II IMPACT study. The drug was given as switch maintenance in 59 patients with metastatic colorectal cancer (mCRC) not progressing after 4.5 to 6 months of induction chemotherapy +/- bevacizumab, considered the most appropriate setting for an agent broadly activating the immune system. MGN1703 showed a superior effect over placebo, with a hazard ratio (HR) for the primary endpoint “PFS on maintenance” of 0.55 (p=0.041) by local assessment. Exploratory PFS analyses of pretreatment characteristics identified patients with objective RECIST response, normalized CEA and presence of activated NKT cells at the end of induction treatment to benefit the most with MGN1703 maintenance. Furthermore, the subgroup of patients with RECIST response after induction therapy reported a HR of 0.40 (median 24.5 vs. 15.1 months) for overall survival (OS). These results warranted confirmation in a larger Phase III study.


The IMPALA study (NCT02077868) is an open-label Phase III trial with participation of AIO, TTD, and GERCOR cooperative groups, designed to confirm the encouraging evidence from IMPACT. mCRC patients having achieved an objective tumor response following first line induction therapy with or without biological agents are randomized to receive MGN1703 switch maintenance monotherapy in the experimental arm or local standard of care in the control arm. In case of relapse, patients will reintroduce the initial induction treatment whenever feasible, with those in the experimental arm continuing to receive MGN1703 therapy. The primary endpoint of the study will be OS. Secondary endpoints include PFS, response rates, safety, and QoL in selected centers. Type of induction treatment, CEA and activated NKT at baseline are stratification factors for the study and will be prospectively assessed. All randomized patients take part in a comprehensive immune monitoring plan evaluating cytokines and chemokines in serum and the activation status of various immune cell populations. Recruitment started in September 2014 and the study is expected to recruit 540 patients within 24 months in 8 European countries.

After more than 100 patients have been recruited, first exploratory immune monitoring data of patient's blood samples confirmed the MoA of MGN1703: A strong activation was observed in monocytes (CD169+), a lesser one in NK cells (CD69+), a moderate activation in NKT cells and T cells (both CD69+). This immune profile is in keeping with data obtained from the previous IMPACT study.

Trial registration identifier NCT02077868.